DaVita Gains 11.5% as Q4 Beats Fuel Expansion to 3,242 Centers
DaVita’s stock gained 11.5% over six months versus industry’s 2.6% and S&P’s 6.3%, backed by a $10.34 billion market cap and projected 20.2% five-year growth. The company beat estimates in three of four trailing quarters, operates 3,242 dialysis centers for 295,000 patients, and faces reimbursement risk from 26% commercial payer revenue.
1. Six-Month Performance and Outlook
DaVita’s shares rose 11.5% over the past six months versus 2.6% industry growth and 6.3% for the S&P 500, underpinned by a $10.34 billion market cap and management’s projection of 20.2% earnings growth over the next five years.
2. Q4 2025 Earnings Highlights
In the fourth quarter, DaVita surpassed consensus estimates in three of the trailing four quarters with an average EPS surprise of 1.2%, delivered revenue and rate per treatment upticks, expanded margins through new center openings and acquisitions, and launched a clinical partnership with Elara Caring for home-based end-stage kidney care.
3. Integrated Kidney Care Model
The patient-centric platform integrates dialysis, transplants and value-based arrangements, with DaVita participating in the CMMI Comprehensive Kidney Care Contracting model to slow late-stage CKD progression, increase home dialysis adoption and enhance care coordination through joint ventures with nephrologists and providers.
4. International Expansion and Payer Mix Risk
DaVita operates 3,242 outpatient centers—including 585 across 14 countries—serving 295,000 patients, with recent acquisitions in Europe and Asia; however, its 26% commercial payer revenue concentration versus 89% government coverage exposes the company to reimbursement pressure if payer mix shifts.